Live·Open questions in longevity research
All news
Clinical trialsTherapeuticsIndustry & policy

A single infusion of Intellia’s liver gene-editing therapy kept hereditary angioedema under control for up to four years, according to company data released ahead of an FDA decision

16 November 2026· 261116011

A single infusion of Intellia’s liver gene-editing therapy kept hereditary angioedema under control for up to four years, according to company data released ahead of an FDA decision

On November 12, Intellia released data on 32 patients who received 50 mg of lonvoguran ziclumeran (lonvo-z) in early trials. Levels of kallikrein, the enzyme that generates the swelling-inducing molecule bradykinin, fell by an average of 84% at four weeks and remained reduced for up to four years. The FDA is expected to decide on the application by March 10, 2027.

In hereditary angioedema types 1 and 2, the body has insufficient functional C1 inhibitor, a protein that restrains the cascade of reactions that produces bradykinin. Excess bradykinin makes blood vessels leaky, causing swelling in the larynx, abdomen, or limbs. Drugs that block kallikrein or its production require lifelong use. Lonvo-z is designed to replace them with a single infusion. Lipid nanoparticles deliver instructions for making Cas9, a DNA-cutting CRISPR enzyme, into liver cells, along with a guide RNA that targets the KLKB1 gene. The liver uses this gene to produce prekallikrein, the precursor of kallikrein. Errors introduced as the cell repairs the cut disable the gene.

Before the infusion, patients had an average of 3.4 attacks per month. After the first year, at least 90% of patients under observation were attack-free in each month. At the latest assessment, all 32 were off regular prophylaxis, and 29 had not started it after the infusion. Median follow-up was 20.8 months; seven patients had reached three years, and the longest follow-up was 46.5 months.

The authors of the first trial compare lonvo-z recipients with people born without prekallikrein: people with reported cases of this condition, Fletcher deficiency, appear healthy. The first trial’s protocol set a 60% reduction in kallikrein as the threshold for dose selection, based on results from a trial of a drug targeting this enzyme. In patients receiving a drug that suppresses prekallikrein production, a reduction of this size was associated with almost complete control of attacks.

All three doses in phase one met the threshold; 25 and 50 mg were selected for phase two. In that trial, 25 mg reduced kallikrein by 55%, and 50 mg reduced it by 86%; 4 of 10 and 8 of 11 patients, respectively, remained attack-free over 16 weeks. Based on these two measures, Intellia selected 50 mg for phase three. In that trial, HAELO, patients had 87% fewer attacks over six months than those receiving placebo.

The liver renews itself over four years: estimates from radiocarbon dating suggest that more than half of an adult’s liver cells formed within the past year. The edit is encoded in liver cell DNA, and animal experiments suggest that it passes to daughter cells: in mice, the extent of editing changed little after 70% of the liver was removed and the liver regrew. If daughter cells lost the edit, kallikrein levels would rise as cells were replaced. Intellia considers the sustained reduction in kallikrein confirmation that the edit is working as intended.

Another Intellia therapy, nex-z, uses the same nanoparticles and Cas9: the authors of the first trial write that it differs from lonvo-z only in 20 “letters” of the guide RNA. On October 29, 2025, the FDA placed two nex-z trials on hold after a patient developed severe liver injury and subsequently died of septic shock; the holds were lifted in 2026. Among the 32 patients who received lonvo-z, two had temporary, asymptomatic increases in blood liver enzymes to grade two, classified as moderate, the highest grade observed in the group.

The only FDA-approved CRISPR therapy, Casgevy, edits cells removed from the body and requires intensive chemotherapy, Nature reports. If the FDA approves lonvo-z, it will become the first CRISPR drug to edit genes inside the body.

Originally published on Telegram by Ukhvat NewsView on Telegram
Sources
#lonvo-z#hereditary-angioedema#crispr#in-vivo-gene-editing#kallikrein#intellia